NVCR News and Press, NovoCure Limited From 02/24/22

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q4 earnings call. For further details see: NovoCure Limited 2021 Q4 - Results - Earnings Call Presentation

NovoCure press release (NASDAQ:NVCR): Q4 GAAP EPS of -$0.25 misses by $0.15. Revenue of $133.21M (-7.5% Y/Y) misses by $1.28M. The company expects to achieve active patient growth between 2% to 5% in 2022, in-line with the growth rate experienced in the fourth quarter of 2021. Longer term, th...

Tumor Treating Fields dually activates the STING and AIM2 pro-inflammatory signaling pathways that drive early anti-tumor immune responses Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment wi...

Full year 2021 net revenues of $535 million, an increase of 8% year-over-year Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology Novocure (NASDAQ: NVCR) today reported financia...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.10 (-350.0% Y/Y) and the consensus Revenue Estimate is $134.49M (-6.6% Y/Y). Over the last 1 year, NVCR has beaten EPS estimates 25% of the tim...

So far in 2022, the stock market has been ugly, and stocks have been hammered across the board, including healthcare stocks. Is it possible to find some future winners in this bear market? Sure. When the world turns awful, healthcare is usually a bright spot. Upheaval in Ukraine means m...

The mini-crash of January has given investors the opportunity to buy some amazing healthcare companies at a discount. First we're going to take a look at Doximity (NYSE: DOCS) , a telehealth powerhouse that is almost 60% off its highs. Next up is Novocure (NASDAQ: NVCR) , a ...

Oppenheimer has upgraded shares of NovoCure (NVCR +1.6%) from perform to outperform citing the company's current valuation and growth from the release of next-generation arrays mid year. The firm has a $98 price target (~37% upside based on yesterday's close). Analyst Kevin DeGeeter wrote tha...

Shares of Novocure (NASDAQ: NVCR) have plunged more than 70% below their highs set last summer. What should investors do? In this Motley Fool Live video recorded on Jan. 19 , Motley Fool contributors Keith Speights and Brian Orelli talk about why focusing on the long-te...

Shares of Novocure Limited (NASDAQ: NVCR) are jumping 12.9% higher as of 11:09 a.m. ET on Thursday. The solid gain came after investment firm Truist Financial upgraded the stock from a hold to a buy recommendation. Truist kept its 12-month price target for the stock at $125, which r...